Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer.
To compare long-term (4-10 years) quality of life (QoL) of men with low-risk prostate cancer (PCa) treated by different modalities and a reference group without PCa.



In this cross-sectional study, four groups were sent a one-time QoL-questionnaire; PCa patients (1) following the structured Prostate cancer Research International Active Surveillance protocol, (2) who underwent radical prostatectomy (RP) in the context of the European Randomized study of Screening for Prostate Cancer-section Rotterdam, (3) who underwent radiotherapy (RT) at an academic hospital in The Netherlands, and (4) an age-matched reference group of men without PCa. The QoL-questionnaire addressed prostate-specific health (EPIC), generic health (SF-12), and anxiety (STAI-6). Statistical significance (p ≤ 0.05) and clinical relevance (≥0.5 SD) of differences between groups were assessed.



The AS, RP, RT, and reference group response rates amounted to 74% (122/165), 66% (70/106), 66% (221/335), and 75% (205/273), respectively. At a mean of 6.6 years of follow-up, active surveillance (AS)-men reported better urinary function [M = 93.0 (SD = 10.6) vs. 80.0 (SD = 19.1), p ≤ 0.001], less urinary incontinence [M = 90.0 (SD = 14.6) vs. 70.1 (SD = 28.8), p ≤ 0.001], and better sexual function [M = 40.9 (SD = 24.6) vs. 14.8 (17.7), p ≤ 0.001, clinically relevant] than RP-men. Compared to RT, AS-men reported better sexual function [M = 40.9 (SD = 24.6) vs. 25.8 (SD = 25.0), p = 0.069]. The four groups reported similarly low anxiety levels; the number of highly anxious men (STAI ≥ 44) ranged from 8 to 13%. For all QoL domains, men on AS and men without PCa reported very similar scores.



Prostate-specific function of AS-men was significantly better than that of RP-men. When comparing AS to RT, a borderline significant difference in sexual function was seen. Men who followed an AS strategy for a long-term period were not anxious and accepted it well, suggesting that AS may be a good treatment option for men with low-risk PCa.
Department of Urology, Erasmus University Medical Center, Room Na1710, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. l.venderbos@erasmusmc.nl.|Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands. l.venderbos@erasmusmc.nl.
Lionne D F
LDF
Venderbos
Department of Urology, Erasmus University Medical Center, Room Na1710, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.|Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Shafak
S
Aluwini
Department of Urology, Erasmus University Medical Center, Room Na1710, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Monique J
MJ
Roobol
Department of Urology, Erasmus University Medical Center, Room Na1710, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Leonard P
LP
Bokhorst
Department of Urology, Amphia Hospital, Breda, The Netherlands.
Eric H G M
EHGM
Oomens
Department of Urology, Erasmus University Medical Center, Room Na1710, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Chris H
CH
Bangma
Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands.
Ida J
IJ
Korfage
D000368:Aged; D003430:Cross-Sectional Studies; D062665:Epidemiological Monitoring; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000523:psychology*; D011788:Quality of Life / Q000523:psychology*; D011795:Surveys and Questionnaires
Active surveillance; Patient reported outcome; Quality of life; Radical prostatectomy; Radiotherapy; Shared decision-making